Addendum

Vosoritide (achondroplasia, ≥ 2 years) – Addendum to Project A23-92

Report documents

Indication:

Patients with achondroplasia 2 years of age and older whose epiphyses are not closed

Result of dossier assessment:

Unchanged after addendum: indication of non-quantifiable added benefit

2024-02-15 A G-BA decision was published.

Project no.: A24-08
Commission: Commission awarded on 09.01.2024 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Muscles, bones and joints
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://dx.doi.org/10.60584/A24-08

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.